SEARCH ARTICLES



LATEST ARTICLES

Table of Contents

2020 Month : January Volume : 9 Issue : 4 Page : 191-194

Comparison of Efficacy and Safety of Theophylline, Doxophylline and Acebrophylline as an Add-On in the Management of Chronic Obstructive Pulmonary Disease.

Ranjit Gain1, Rupam Kumar T. A.2, Pronoy Sen3, Vignesh A.4

1Department of Biochemistry, Burdwan Medical College and Hospital, Bardhaman, West Bengal, India. 2Department of Chest Medicine, Burdwan Medical College and Hospital, Bardhaman, West Bengal, India. 3Department of Chest Medicine, Burdwan Medical College and Hospital, Bardhaman, West Bengal, India. 4Department of Pulmonary Medicine, Burdwan Medical College and Hospital, Bardhaman, West Bengal, India.

References :

1

Global strategy for diagnosis, management and prevention of COPD – 2016.  Global initiative for chronic obstructive lung disease - GOLD. [cited 2016 Nov 11]. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/

2

Gupta D, Agarwal R, Aggarwal AN, et al. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India Off Organ Indian Chest Soc 2013;30(3):228-67. http://www.who.int/respiratory/copd/burden/en/       

CrossRef | Google Scholar | PubMed
3

Molfino NA, Zhang P. A meta-analysis on the efficacy of oral theophylline in patients with stable COPD. Int J Chron Obstruct Pulmon Dis 2006;1(3):261-6.   

CrossRef | Google Scholar | PubMed
4

Gaudreault P, Guay J. Theophylline poisoning. Pharmacological considerations and clinical management. Med Toxicol 1986;1(3):169-91.          

CrossRef | Google Scholar | PubMed
5

Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003;167(6):813-8.             

CrossRef | Google Scholar | PubMed
6

Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005;2(4):334-9, discussion 340-1.           

CrossRef | Google Scholar | PubMed
7

Dini FL, Cogo R. Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects. Curr Med Res Opin 2001;16(4):258-68. 

PubMed
8

Sacco C, Braghiroli A, Grossi E, et al. The effects of doxofylline versus theophylline on sleep architecture in COPD patients. Monaldi Arch Chest Dis 1995;50(2):98-103.           

Google Scholar | PubMed
9

Shukla D, Chakraborty S, Singh S, et al. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother 2009;10(14):2343-56.            

CrossRef | Google Scholar | PubMed
10

Tapadar SR, Das M, Chaudhuri AD, et al. The effect of acebrophylline vs sustained release theophylline in patients of copd- a comparative study. J Clin Diagn Res 2014;8(9):MC11-MC4.             

CrossRef | Google Scholar | PubMed
11

Pozzi E. Acebrophylline: an airway mucoregulator and anti-inflammatory agent. Monaldi Arch Chest Dis 2007;67(2):106-15.       

CrossRef | Google Scholar | PubMed
12

Agliati G. Effects of a short course of treatment with acebrophylline on the mucus rheological characteristics and respiratory function parameters in patients suffering from chronic obstructive pulmonary disease. J Int Med Res 1996;24(3):302-10.        

CrossRef | Google Scholar | PubMed